- Malignant MCA syndrome may be seen following a large MCA territory infarct.
- It usually occurs 2-5 days post onset of stroke but sometime can occur earlier within 24 hrs.
- There is localised cytotoxic oedema, swelling and often midline shift.
- Trials have shown that surgery both reduces mortality and improves functional status but also results in the survival of more patients with severe disability.
- MCA occlusion may be due to atheroembolism
- Cardioembolism from AF or structural cardiac disease
- Carotid dissection may embolise to the MCA
- Left/Right MCA syndrome
- Progressive reduced level of consciousness
- Pupillary changes and Cheyne-Stokes respiration
- CT scan initially may be normal or show a hyperdense artery. Overtime there is progressive hypodensity and obvious cytotoxic oedema and midline shift.
- MRI will show infarct volume and extent
|RCP Guidance 2016|
|Patients with middle cerebral artery (MCA) infarction who meet the criteria below should be considered for decompressive hemicraniectomy. Patients should be referred to neurosurgery within 24 hours of stroke onset and treated within 48 hours of stroke onset:
- Even with ICP management with endotracheal intubation, blood pressure control, osmotherapy, hyperventilation, and barbiturate anaesthesia for refractory intracranial hypertension, mortality rates of up to 80% have been reported.
- Decompressive hemicraniectomy with durotomy involves the removal of a large flap of bone and the layer of dura that lies over the brain. The brain can herniate beyond the confines of the skull. The result is that brainstem compression is less likely, and survival increased.
- Patient selection will depend upon the patient's known views and wishes as to how they would wish to be managed. A poor functional baseline with significant co morbidities may suggest surgery is not in the patientâ€™s best interests. Involvement of the PCA and/or ACA on imaging would suggest a poorer outcome. AN infarct volume > 145 cm on DWI is also associated with poorer outcomes.
- There was previously a cut off age of 60 but the DESTINY II trial of decompressive hemicraniectomy for older patients showed a substantial survival benefit for patients over the age of 60 years (Juttler et al, 2014) akin to that seen in young patients (Cruz-Flores et al, 2012). Decisions to undertake major life-saving surgery need to be carefully considered on an individual basis, but patients should not be excluded from treatment by age alone
|Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicentre, open, randomised trial Lancet Neurol. 2009 Apr;8(4):326-33||HAMLET investigators||Surgical decompression reduces case fatality and poor outcome in patients with space-occupying infarctions who are treated within 48 h of stroke onset. There is no evidence that this operation improves functional outcome when it is delayed for up to 96 h after stroke onset. The decision to perform the operation should depend on the emphasis patients and relatives attribute to survival and dependency.|
|Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY) Stroke 2007;38:2518-2525||DESTINY Study Group||DESTINY showed that hemicraniectomy reduces mortality in large hemispheric stroke. With 32 patients included, the primary end point failed to demonstrate statistical superiority of hemicraniectomy, and the projected sample size was calculated to 188 patients. Despite this failure to meet the primary end point, the steering committee decided to terminate the trial in light of the results of the joint analysis of the 3 European hemicraniectomy trials.|
|Hemicraniectomy in Older Patients with Extensive Middle-Cerebral-Artery Stroke N Engl J Med 2014; 370:1091-1100||DESTINY II Investigators||Hemicraniectomy increased survival without severe disability among patients > 60 years of age with a malignant MCA Infarction. The majority of survivors required assistance with most bodily needs. DESTINY II Current Controlled Trials number,|
|Note: The plan is to keep the website free through donations and advertisers that do not present any conflicts of interest. I am keen to advertise courses and conferences. If you have found the site useful or have any constructive comments please write to me at drokane (at) gmail.com. I keep a list of patrons to whom I am indebted who have contributed. If you would like to advertise a course or conference then please contact me directly for costs and to discuss a sponsored link from this site.|